Spruce Biosciences, Inc. Proceeds from Issuance of Debt
Spruce Biosciences, Inc. (SPRB) reported Proceeds from Issuance of Debt of $4.49 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2021-03-22
- Spruce Biosciences, Inc. proceeds from issuance of debt for the quarter ending 2019-12-31 was $2.00M.
- Spruce Biosciences, Inc. proceeds from issuance of debt for fiscal 2019 was $4.49M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|
| 2019-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $4.49M 10-K · filed 2021-03-22 | |
| 2019-09-30 | $2.49M 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |